Six-months immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: Updated results of the Vax-On study
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
The prospective Vax-On study was conducted at our institution as part of introducing SARS-CoV-2 mRNA-BNT162b2 (tozinameran) vaccination in actively treated cancer patients. Our preliminary findings confirmed a favorable safety profile and suggested that proximity to treatment hampers immune response to the first vaccine dose (timepoint-2). The second dose induced an exponential rise in anti-Spike protein IgG titer and seroconversion rates up to >90%, abrogating the disparity between the cohorts (timepoint-3)1. Herein, we report on antibody response assessment scheduled six months after the first tozinameran dose (timepoint-4).
Annals of Oncology , commentaire en libre accès, 2021